Where Alzheimer's came from: an ancient gene in a modern world
Last reviewed November 15, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Alzheimer's disease isn't caused by one gene, but one version of one gene matters more than any other: APOE4. Carrying it raises the risk substantially, and it is common, found in roughly 1 in 5 people worldwide.
That raises an old puzzle. If a gene version is this harmful, why is it still so common? The answer researchers are converging on is that it wasn't always harmful. This page follows that story. For how the disease was first recognized, see our page on the history of Alzheimer's.
Related pages: Memory loss and dementia (Alzheimer's)
The bottom line
- APOE4 is the ancestral version of the gene. It is what all humans carried before the other versions appeared.
- It is the strongest common genetic risk factor for Alzheimer's.
- Most people who carry APOE4 never develop Alzheimer's, and many people with Alzheimer's don't carry it.
- Why APOE4 stayed common. Benefits in childhood, in fighting infection, and in fertility have all been proposed.
- Whether Alzheimer's was rare in the distant past, or simply unrecorded because few people lived long enough.
The story, step by step
- 1. The oldest version (Genetics researchers, from the 1990s onward)
- 2. What it costs today (Many large studies)
- 3. Once an advantage (Trumble, Gurven, Finch, Kaplan and others, 2017 to 2023)
- 4. The mismatch (A theory built from several lines of research)
APOE4 is the version humans started with
What happened
The APOE gene makes a protein that moves cholesterol and fats around the body and brain. It comes in three common versions: APOE2, APOE3 and APOE4. Researchers compared them across species and populations to work out which came first.
What the evidence shows
- APOE4 is the ancestral version. Our closest primate relatives carry the equivalent of it.
- APOE3, now the most common version in people, appeared later, by one estimate around 200,000 years ago.
- APOE4 remains common, with carrier rates ranging from about 5% to 45% depending on the population.
Why it matters
Alzheimer's risk isn't a new mutation that crept in. The risk version is the old one, and the protective versions are the newcomers.
What's still uncertain
- Dating gene versions relies on statistical models and comes with wide margins.
Read more
Next: What it costs today
In modern populations, APOE4 raises the risk sharply
What happened
Researchers compared Alzheimer's rates in people with zero, one or two copies of APOE4.
What the evidence shows
- One copy raises the risk roughly three-fold compared with people who have none.
- Two copies, one from each parent, raise it considerably more. Estimates commonly run about 8 to 12 times.
- APOE4 also tends to bring symptoms on earlier, and raises the risk of side effects from the new amyloid-clearing drugs.
Why it matters
This is why APOE4 is the most studied gene in dementia research.
What's still uncertain
- These are group odds, not personal fortune-telling. Plenty of people with two copies never get Alzheimer's.
- Most of the large studies were in people of European ancestry. The effect appears weaker in some African and Hispanic populations, which is itself a clue.
Read more
- National Institute on Aging: Alzheimer's disease geneticsGovernment
- OwieClear deep dive: What really happens in Alzheimer'sOwieClear
Next: Once an advantage
In a world full of parasites, APOE4 carriers did better
What happened
The Tsimane live with high parasite and infection loads and little of modern life's comfort, closer to the conditions humans spent most of their history in. Researchers tested their thinking skills, measured parasite loads and immune markers, and genotyped them.
What the evidence shows
- Among Tsimane with heavy parasite loads, APOE4 carriers held their thinking skills steady or even improved, while non-carriers declined. In low-parasite conditions, the usual pattern returned.
- APOE4 carriers had about 30% lower levels of C-reactive protein, a marker of inflammation, along with higher cholesterol that could fuel an immune response.
- A later study of 795 Tsimane women found APOE4 carriers had their first child earlier and had shorter gaps between births.
Why it matters
This is the leading explanation for the puzzle. In a world of infections and scarce food, a gene that keeps fats available and tunes the immune response was worth having, enough to outweigh a disease that strikes late in life, long after children are raised.
What's still uncertain
- These are observations in one population, not an experiment, and the sample sizes are modest.
- Other explanations exist, including that natural selection simply pays little attention to diseases of old age.
Read more
- Trumble 2017, FASEB Journal (PubMed)PubMed
- Garcia 2021, eLifeJournal
- Trumble 2023, Science AdvancesJournal
Next: The mismatch
An ancient setting, a modern lifespan
What happened
Researchers put the genetics together with what raises dementia risk today.
What the evidence shows
- People now live decades past the age when these genes had any effect on survival or having children.
- Modern life brings far fewer parasites, but more of what the Lancet Commission lists as dementia risks: untreated hearing and vision loss, high blood pressure, diabetes, smoking, inactivity, air pollution and social isolation.
- Addressing those 14 risk factors could prevent or delay an estimated 45% of dementia worldwide.
Why it matters
The practical point is hopeful: the part you inherit is fixed, but it's only part. The risk factors that account for close to half of dementia are the ones you and your doctor can act on.
What's still uncertain
- The mismatch idea ties findings together, but it hasn't been tested as a whole and probably never can be.
- It doesn't explain the rare inherited forms of Alzheimer's that strike in middle age.